Abbott to Acquire Global Rights to Action Pharma’s Phase II Acute Kidney Injury Drug
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 5 (Table of Contents)
Published: 14 May-2012
DOI: 10.3833/pdr.v2012.i5.1742 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Abbott is to acquire worldwide development and commercialisation rights to Action Pharma’s AP214, an alpha-MSH (melanocyte-stimulating hormone) peptide derivative in Phase IIb development for the prevention of acute kidney injury associated with major cardiac surgery, for a one-time cash payment of US$110 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS